A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients — TARGET-D  

Myocardial Infarction Clinical Trial

Official title: A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients (The TARGET-D Study)

Status Active, not recruiting

Clinical Trial Summary

This study evaluates whether achieving 25-hydroxyvitamin D (25[OH] Vit D) levels (>40 ng/mL) among myocardial infarction patients will result in a reduction of cardiovascular-related adverse events. Half of the patients will be randomized to receive standard of care and half will receive clinical management of 25[OH] Vit D levels.

Clinical Trial Description

Low 25[OH] Vit D levels have become a public epidemic with increasing recognition of its widespread insufficiency both in the United States and worldwide. Epidemiologic studies have associated low 25[OH] Vit D levels with coronary risk factors and adverse cardiovascular outcomes. However, randomized trials are needed to establish the relevance of 25[OH] Vit D status to cardiovascular health. While a few randomized trials have evaluated vitamin D supplementation, none have "treated to target" (i.e., individual dosing so that adequate 25[OH] Vit D levels are obtained), but have rather given "blanket" doses regardless of 25[OH] Vit D level. ;

Related Conditions & MeSH terms

• Cerebral Vascular Accident
• Death
• Heart Failure Hospitalization
• Infarction
• Myocardial Infarction
• Stroke

• NCT number: NCT02996721
• Study type: Interventional
• Source: Intermountain Health Care, Inc.
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: April 3, 2017
• Completion date: May 31, 2024